| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2025-070 | | --- | --- | --- | | 债券代码：113610 | 债券简称：灵康转债 | | 灵康药业集团股份有限公司 重要内容提示： 灵康药业集团股份有限公司（以下简称"灵康药业"、"公司"）股票 自 2025 年 9 月 29 日至 2025 年 10 月 29 日已有 10 个交易日的收盘价低于当期转 股价格的 85%（5.53 元/股），存在触发《灵康药业集团股份有限公司公开发行 可转换公司债券募集说明书》（以下简称"《募集说明书》"）中规定的转股价 格向下修正条件的可能性。若触发条件，公司将于触发条件当日召开董事会审议 决定是否修正转股价格，并及时履行信息披露义务。 关于"灵康转债"预计满足转股价格修正条件的提示 性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 （二）经上海证券交易所自律监管决定书[2020]412 号文同意，公司发行的 525,000,000 元可转换公司债券于 2020 年 12 月 22 ...

Core Viewpoint - Lingkang Pharmaceutical announced participation in the 11th national centralized drug procurement, with its product, injectable cefoperazone sodium, expected to be selected for procurement, indicating potential revenue growth for the company [1] Company Summary - Lingkang Pharmaceutical's wholly-owned subsidiary, Hainan Lingkang Pharmaceutical Co., Ltd., will participate in the national centralized procurement from October 27 to October 28, 2025 [1] - The projected sales for injectable cefoperazone sodium in 2024 are approximately 23.01 million yuan, accounting for 6.06% of the company's total revenue for that year [1] - For the first half of 2025, the sales of the same product are estimated at 1.82 million yuan, representing 1.06% of the company's revenue for that period [1] - The revenue composition for Lingkang Pharmaceutical in 2024 is as follows: pharmaceuticals 84.62%, pharmaceutical distribution 12.19%, other businesses 2.7%, and hospital sales and distribution 0.48% [1] - As of the report, Lingkang Pharmaceutical has a market capitalization of 4 billion yuan [1]

Core Viewpoint - Lingkang Pharmaceutical (603669.SH) announced that its wholly-owned subsidiary, Hainan Lingkang Pharmaceutical Co., Ltd., participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, with its product, injectable cefoperazone sodium, expected to be selected in this procurement process [1] Group 1 - Lingkang Pharmaceutical's subsidiary is involved in a significant national drug procurement initiative [1] - The product under consideration for selection is injectable cefoperazone sodium [1]

证券代码：603669 证券简称：灵康药业 公告编号：2025-069 公司全资子公司灵康制药的注射用头孢唑肟钠2024年销售额为2,300.89万 元，占公司 2024 年度营业收入比例为 6.06%；2025 年半年度销售额为 181.83 万 元，占公司 2025 年半年度营业收入比例为 1.06%。 本次药品集中采购是国家组织的第十一批国家药品集中采购，采购周期中， 医疗机构将优先使用本次药品集中采购中选药品，并确保完成约定采购量。本次 公司全资子公司灵康制药拟中选药品的价格较拟中选省份现销售价格相比存在 一定程度下降。若拟中选产品确定中选后将签订购销合同并实施，将有利于促进 灵康药业集团股份有限公司 关于子公司参与全国药品集中采购拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2025 年 10 月 27 日至 2025 年 10 月 28 日，灵康药业集团股份有限公司（以 下简称"公司"）全资子公司海南灵康制药有限公司（以下简称"灵康制药"） 参加了国家组织药品联合采购办公室（以下简称"联采办" ...

Market Overview - The chemical pharmaceutical sector increased by 0.82% on the previous trading day, with Jinshi Yao leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Top Gainers in Chemical Pharmaceutical Sector - Jinshi Yao (300434) closed at 11.39, up 11.78% with a trading volume of 640,000 shares and a turnover of 714 million yuan [1] - Guangji Pharmaceutical (000952) closed at 7.06, up 9.97% with a trading volume of 215,600 shares and a turnover of 150 million yuan [1] - New Ganjing (920367) closed at 23.21, up 9.02% with a trading volume of less than 37,000 shares and a turnover of 85.7 million yuan [1] - Lingkang Pharmaceutical (603669) closed at 5.97, up 7.37% with a trading volume of 327,700 shares and a turnover of 192 million yuan [1] - Xiangdi Pharmaceutical (301211) closed at 13.12, up 6.84% with a trading volume of 190,800 shares and a turnover of 249 million yuan [1] Top Losers in Chemical Pharmaceutical Sector - Anglikang (002940) closed at 38.92, down 6.58% with a trading volume of 210,700 shares and a turnover of 829 million yuan [2] - Shutaishen (300204) closed at 36.99, down 5.57% with a trading volume of 394,900 shares and a turnover of 1467 million yuan [2] - Yatai Pharmaceutical (002370) closed at 7.00, down 4.76% with a trading volume of 1,532,900 shares and a turnover of 1061 million yuan [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 421 million yuan from institutional investors and 643 million yuan from speculative funds, while retail investors saw a net inflow of 1.063 billion yuan [2][3] - Jinshi Yao (300434) had a net inflow of 98.99 million yuan from institutional investors, while retail investors had a net outflow of 71.82 million yuan [3] - Guangji Pharmaceutical (000952) saw a net inflow of 39.50 million yuan from institutional investors, but a net outflow of 23.01 million yuan from retail investors [3]

Core Viewpoint - The A-share market is experiencing a surge in flu-related stocks, driven by rising flu activity in southern provinces and the emergence of the H3N2 strain, which has led to increased investor interest in pharmaceutical companies [1][2] Company Performance - **Jinshi Yiyao**: Increased by 13.44%, with a total market value of 4.644 billion [2] - **Guangji Pharmaceutical**: Rose by 9.97%, total market value of 2.448 billion [2] - **Te Yi Pharmaceutical**: Gained 8.78%, market value of 5.209 billion [2] - **Hualan Biological Engineering**: Up by 8.59%, with a market value of 12.9 billion [2] - **Lingkang Pharmaceutical**: Increased by 7.01%, market value of 4.291 billion [2] - **Hengdi Pharmaceutical**: Rose by 6.60%, market value of 5.466 billion [2] - **Innotec**: Increased by 5.37%, market value of 4.459 billion [2] - **Weikang Pharmaceutical**: Up by 4.76%, market value of 3.471 billion [2] - **Yirui Biological**: Increased by 4.67%, market value of 4.359 billion [2] Market Trends - The China CDC reported a slow increase in respiratory disease cases nationwide, with flu activity rising in southern provinces and remaining low in northern regions [1] - Experts suggest that the flu season may arrive earlier this year, with a potential increase in infection rates due to lower immunity against the H3N2 strain [1]

Core Viewpoint - Lingkang Pharmaceutical Group Co., Ltd. held its second extraordinary general meeting of shareholders on October 10, 2025, where the fifth board of directors was elected, and key management personnel were appointed [1][5]. Group 1: Board Composition - The fifth board of directors consists of 7 members: 3 non-independent directors, 3 independent directors, and 1 employee representative director [2][3]. - The board is chaired by Ms. Tao Lingping, with Mr. Tao Xiaogang, Mr. Zhang Hui as non-independent directors, and Mr. Wang Hongxin, Ms. Zhu Ming, and Ms. Du Juling as independent directors [2][3]. Group 2: Management Appointments - The company appointed Mr. Tao Xiaogang as the general manager, with Mr. Lü Jun, Mr. Liu Liming, and Mr. Sui Guoping as vice general managers [3][4]. - Mr. Zhang Junke was appointed as the financial director, Mr. Sui Guoping as the board secretary, and Mr. Liao Baoyu as the securities affairs representative [3][4]. Group 3: Committee Structure - The board has established four specialized committees: the Audit Committee, Nomination Committee, Compensation and Assessment Committee, and Strategic Committee, with independent directors holding a majority in the first three committees [3][4]. Group 4: Cancellation of Supervisory Board - The company decided to cancel the supervisory board, transferring its responsibilities to the Audit Committee of the board, in compliance with new regulations effective from July 1, 2024 [5][6]. Group 5: Shareholder Meeting Details - The extraordinary general meeting was legally convened, with all resolutions passed unanimously, including the election of the board and the cancellation of the supervisory board [11][17].

Core Viewpoint - Lingkang Pharmaceutical announced the election of Mr. Liu Liming as the employee representative director of the company's fifth board of directors [2] Company Summary - The announcement was made on the evening of October 10 [2] - The election reflects the company's governance structure and employee representation [2]

Group 1 - The core point of the article is that Lingkang Pharmaceutical announced the election of Ms. Tao Lingping as the new chairperson of the board [2][3]

证券代码：603669 证券简称：灵康药业 公告编号：2025-067 灵康药业集团股份有限公司 关于董事会完成换届选举及聘任高级管理人员、证券 事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 10 日召开 2025 年第二次临时股东大会，会议选举产生了公司 3 名非独立董事及 3 名独立 董事，与公司职工代表大会选举产生的 1 名职工代表董事共同组成第五届董事会。 在完成董事会换届选举后，公司于同日召开第五届董事会第一次会议，选举产生 第五届董事会董事长、各专门委员会委员，并聘任了总经理、副总经理、财务总 监、董事会秘书和证券事务代表。现将公司董事会换届选举及聘任高级管理人员、 证券事务代表的具体情况公告如下： 一、公司第五届董事会组成情况 根据公司职工代表大会、2025 年第二次临时股东大会及第五届董事会第一 次会议选举结果，公司第五届董事会由 7 名董事组成，其中：非独立董事 3 名， 独立董事 3 名，职工代表董事 1 名。公 ...